Monoclonal antibodies and Fc fragments for treating solid tumors
Advances in biotechnology, better understanding of pathophysiological processes, as well as the identification of an increasing number of molecular markers have facilitated the use of monoclonal antibodies and Fc fragments in various fields in medicine. In this context, a rapidly growing number of t...
Main Authors: | Eisenbeis, Andrea M, Grau, Stefan J |
---|---|
Format: | Online |
Language: | English |
Published: |
Dove Medical Press
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266862/ |
Similar Items
-
Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB
by: Stopforth, Richard J., et al.
Published: (2016) -
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
by: Liming Liu
Published: (2017-04-01) -
Microbials for the production of monoclonal antibodies and antibody fragments
by: Spadiut, Oliver, et al.
Published: (2014) -
Human T lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies. A comparison
Published: (1980) -
Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms
by: Pellerin, Alex, et al.
Published: (2015)